Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients - Interaction with ACE insertion/deletion polymorphism

Kidney International

Volumn 69, Issue 8, 2006, Pages 1438-1443

  So, W Y ^a   Ma, R C W ^a   Ozaki, R ^a   Tong, P C Y ^a   Ng, M C Y ^a   Ho, C S ^a   Lam, C W K ^a   Chow, C C ^a   Chan, W B ^a   Kong, A P S ^a   Chan, J C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

ACE inhibition; ACE polymorphism; Chinese; Diabetic nephropathy; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ALLELE; ARTICLE; CHINESE; COHORT ANALYSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME INHIBITION; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SURVIVAL TIME; TREATMENT RESPONSE;

AGED; ALLELES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; GENE FREQUENCY; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENIN-ANGIOTENSIN SYSTEM; SURVIVAL ANALYSIS;

EID: 33646133656     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000097     Document Type: Article

References (31)

1. Dudley CR, Keavney B, Stratton IM et al. UK Prospective Diabetes Study. XV: Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM. Kidney Int 1995; 48: 1907-1911.
2. Fujisawa T, Ikegami H, Shen GQ et al. Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. Diabetes Care 1995; 18: 983-985.
3. Rigat B, Hubert C, Alhenc-Gelas F et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
4. Moriyama T, Kitamura H, Ochi S et al. Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 1995; 6: 1676-1678.
5. Investigators for HOPE study. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
6. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
7. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
8. Okin PM, Devereux RB, Jern S et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003; 108: 684-690.
9. Jacobsen P, Tarnow L, Carstensen B et al. Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol 2003; 14: 2843-2850.
10. Colhoun HM, Lee ET, Bennett PH et al. Risk factors for renal failure: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44(Suppl 2): S46-S53.
11. Tiret L, Rigat B, Visvikis S et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51: 197-205.
12. Yoshida H, Kuriyama S, Atsumi Y et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 1996; 50: 657-664.
13. Fava S, Azzopardi J, Ellard S, Hattersley AT. ACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease. Diabetes Care 2001; 24: 2115-2120.
14. Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, Levine S (eds). The Kidney. 6th edn. WB Saunders: Philadelphia, 2000, pp 1731-1773.
15. Bjorck S, Blohme G, Sylven C, Mulec H. Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy. Nephrol Dial Transplant 1997; 12(Suppl 2): 67-70.
16. Tomino Y, Makita Y, Shike T et al. Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients. Nephron 1999; 82: 139-144.
17. Ng DP, Tai BC, Koh D et al. Angiotensin-l converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14727 subjects. Diabetologia 2005; 48: 1008-1016.
18. Penno G, Chaturvedi N, Talmud PJ et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 1998; 47: 1507-1511.
19. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-867.
20. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14: 1738-1747.
21. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
22. Hebert LA, Falkenhain ME, Nahman NS et al. Combination ACE inhibitor and angiotensin Il receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999; 19: 1-6.
23. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124.
24. Piwernetz K, Home PD, Snorgaard O et al. for the DiabCare Monitoring Group of the St Vincent Declaration Steering Committee. Monitoring the targets of the St Vincent declaration and the implementation of quality management in diabetes care: the DiabCare initiative. Diabetic Med 1993; 10: 371-377.
25. So WY, Ozaki R, Chan NN et al. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients. Hypertension 2004; 44: 294-299.
26. Wang Y, Ng MC, So WY et al. Prognostic effect of insertion/deletion polymorphism of the ACE gene on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes. Diabetes Care 2005; 28: 348-354.
27. Laakso M, Pyorala K. Age of onset and type of diabetes. Diabetes Care 1985; 8: 114-117.
28. Mogensen CE, Vestbo E, Poulsen PL et al. Microalbuminuria and potential confounders. Diabetes Care 1995; 18: 572-581.
29. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
31. Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-644.